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Abstract
Background: Protein C (PC) and protein S (PS) determination is part of the thrombophilia investigation in patients with 
idiopathic venous thromboembolism (VTE). Based on scarce evidence it is a common notion that PC and PS levels 
decrease during the acute phase of VTE, necessitating delay of testing and temporary transition from warfarin to low 
molecular weight heparin. We have previously demonstrated that an abnormal PC or PS result determined within 24 
hours of VTE diagnosis and before the initiation of warfarin needs to be repeated for confirmation ≥3 months after 
starting treatment and ≥14 days after stopping anticoagulation therapy. In the current study, we sought to show that 
normal PC and PS values determined during the acute phase of VTE are not false negatives.
Methods: 99 patients with acute idiopathic VTE who had normal PC and PS determination within the first 24 hours of 
presentation and who subsequently had their oral anticoagulation discontinued after six months of therapy. PC and PS 
determinations were repeated ≥6 months after starting treatment and ≥ 14 days after stopping warfarin. Proportions 
of patients who tested abnormal on the second test were calculated and 95% confidence intervals obtained using the 
Wilson's score method. Data from a previously published study on patients with abnormal initial tests was included for 
comparison.
Results: None of the 99 patients who had normal PC and PS initially had an abnormal result on repeated testing (0%; 
95% CI 0 - 3.7%). Data from the previous study showed that, among patients who initially had abnormal results, 40% 
(95%CI 35.4-84.8%) were confirmed to have low PC and 63.6% (95%CI 16.8-68.7%) low PS on repeated testing. The 
difference between proportions was statistically significant (χ2 p-value < 0.001).
Conclusion: Our results suggest that PC and PS can be determined during the acute phase of VTE and whereas 
abnormal results need to be confirmed with repeat testing at a later date, a normal result effectively rules out 
deficiency with only one test.
Introduction
Venous thromboembolism (VTE) is a common event,
often precipitated by surgery, immobility or active malig-
nancy[1]. Many cases, however, have no clear precipitant
and are defined as idiopathic VTE [2-4]. The diagnostic
work up for these patients includes testing for inherited
and acquired hypercoagulable conditions, usually includ-
ing functional quantitative assays for proteins C and S,
and antithrombin, as well as testing for lupus anticoagu-
lant, antiphospholipid antibodies, activated protein C
resistance (with or without genetic testing for Factor V
Leiden) and determination of the G20210A Prothrombin
gene mutation[4]. Although from a practical standpoint
this group of tests is most conveniently performed at the
time of acute VTE diagnosis, concerns have been raised
in the literature by studies suggesting that acute VTE may
alter the levels of coagulation factors and lead to false
positive (i.e. low) results.
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Specifically, it is commonly believed that proteins C
and S levels are markedly decreased during the initial
phases of VTE, presumably secondary to consumption of
these factors, thus rendering them uninterpretable. The
evidence that protein C and S levels are decreased during
an acute VTE event is based on a study by D'Angelo et al
[5]. This was a small series of 8 patients and only reported
a lower mean protein C and S level and not the propor-
tion of patients who had an abnormal result. Historically,
some consider that protein C and S can also be falsely ele-
vated on the basis of being acute phase reactants though
there is no documented evidence to substantiate this
claim. Thus, the idea that these levels could not be accu-
rately measured during an acute event has since been
incorporated into medical dogma without being further
validated [2-4,6-9]. Given the fact that these proteins are
vitamin K dependant, late testing requires temporary
interruption of oral anticoagulant therapy for at least 10
days and, in some cases, bridging anticoagulation with
alternative agents such as low molecular weight heparin
(LMWH) with the inherent costs and inconvenience.
Our group previously published data on 254 patients
with acute VTE in whom proteins C and S were deter-
mined within 24 hours of diagnosis before the initiation
of oral anticoagulation[10]. Abnormal results were
repeated at least 3 months after starting treatment and at
least 14 days after stopping anticoagulant therapy. This
study identified that the initial false positive rate for all
protein C and protein S tests was only 2.2% and almost
98% of patients had correct results as assessed at diagno-
sis. A criticism of this study was that we did not repeat
the normal results to ensure that these were not false neg-
atives. In the current study we sought to verify patients
with initially normal protein C and S determinations
were, in fact, true normals by repeating their testing after
anticoagulant therapy was discontinued.
Methods
Patients
We studied consecutive patients referred to the outpa-
tient thromboembolism clinics at a university hospital
with a diagnosis of acute symptomatic VTE objectively
confirmed by previously described criteria[11,12] All
patients were at least 18 years old. Exclusion criteria
were: previous venous thromboembolic events, therapy
with low molecular weight heparin for >48 h prior to test-
ing, abnormal baseline international normalized ratio or
activated partial thromboplastin time (aPTT), active
malignancy, VTE secondary to transient risk factor, preg-
nancy, presentation in the first six weeks postpartum,
known chronic liver disease (defined as persistent eleva-
tion above normal levels of alanine aminotransferase or
gamma glutamyl transferase) and oral anticoagulant ther-
apy (warfarin) in the previous 2 weeks.
Thrombophilia Testing
Samples for thrombophilia testing were drawn prior to
the initiation of oral anticoagulant therapy and within 24
h of diagnosis of venous thromboembolism for all
patients. Blood samples were collected in 0.109 M (3.2%)
sodium citrate tubes (Becton_Dickinson, NJ, USA).
Plasma was obtained and samples were spun at 2000 g for
20 minutes twice at 20°C and then frozen at -70°C and
tested in batches on a weekly basis. Protein C was mea-
sured on an ACL 9000 Coagulometer (Instrumentation
Laboratories, Lexington, MD, USA) using IL Test ProClot
(Instrumentation Laboratory) reagent. Protein S was
measured on an ACL 3000 Coagulometer by the method
of IL-Test protein S (Instrumentation Laboratory). The IL
Test ProClot kit is a functional clotting protein C assay,
based on the prolongation of the aPTT in the presence of
activated protein C. The IL Test protein S kit is a func-
tional clot based assay of free protein S. If a patient's ini-
tial testing of protein C or protein S were normal, the
results were repeated after at least 6 months of anticoagu-
lation therapy provided the patient had discontinued
warfarin for at least 14 days. Patients who had initially
abnormal tests were excluded from this study. At the time
of study our laboratory normal range for protein C was
0.72-1.23 U/ml and the normal range for protein S was
0.60-1.60 U/ml. The previously published study used the
same methods for PC and PS determination as the cur-
rent study.
Statistical analysis
The proportion of patients who tested abnormal on the
second test was determined and confidence intervals for
proportions were determined by the Wilson's score
method[13] using OpenEpi version 2.3[14]. For compari-
son purposes data from the previous study was included
and analyzed in the same way. Comparison between
groups was done using χ2 tests with 2-sided p-values <
0.05 considered to be statistically significant. A post-hoc
analysis to determine the appropriateness of our sample
to detect the observed proportion of false positive results
on repeat testing showed that a sample size of 100 would
be adequate to detect a 3.7% upper confidence bound at
the 97.5% level of significance assuming a true sample
proportion of 0.
Results
Ninety-nine patients with normal protein C and S deter-
minations during the acute phase of VTE diagnosis were
included in the study. There were 47 men and 52 women
with a median age of 56 years (range 21-87). 50 patients
had a diagnosis of deep vein thrombosis, 45 had a diagno-
sis of pulmonary embolism and 4 had concomitant deep
vein thrombosis and pulmonary embolism. All patients
had idiopathic VTE events. On repeat testing after anti-Minuk et al. Thrombosis Journal 2010, 8:10
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coagulant therapy discontinuation, none of the 99
patients had an abnormal result of either protein C or S
(0%, 95% CI 0-3.7%) (Table 1). Data from our previous
study on patients with initially abnormal protein C and S
determination was then used for comparison. Among
patients who initially had abnormally low results, 40%
(95%CI 35.4-84.8%) were confirmed to have low protein
C and 63.6% (95%CI 16.8-68.7%) low protein S on
repeated testing (Table 1). The difference of proportions
between groups was statistically significant (χ2 p-value <
0.001).
Discussion
Thrombophilia screening, including protein C and S
determinations is an important part of the diagnostic
investigation for idiopathic VTE in order to determine
etiology, duration of anticoagulation, and to guide family
testing [7,8,15]. It is widely believed that assays for natu-
ral coagulation inhibitors cannot be performed during
the acute phase of VTE due to a consumptive decrease in
protein C and S leading to false positive testing. This
assumption is based on the study by D'Angelo et al that
identified a mean decrease in protein S activity in patients
with acute VTE before warfarin therapy[5]. This transient
state of acquired protein S deficiency was thought to be a
result of increase in C4bBP levels secondary to inflamma-
tion. The study only examined 8 patients and provided
only a mean protein S level rather than showing the pro-
portion of patients that had a level below the reference
range. The authors of this study commented that these
results would need to be repeated before concluding that
acute VTE falsely lowers levels of protein S. These results
have not been replicated in any further studies and, to our
knowledge, the only other studies investigating this issue
are our previous study in 2006 and this follow up study.
Our previous study in 254 patients with acute VTE
showed that 91% of patients had normal protein C and S
levels and among those with abnormal initial tests 4/12
and 6/12 were proven to have PC and PS deficiency at a
later date. This figure resulted in a sensitivity of 100% and
specificity of 97% and 98% respectively with the caveat
that patients with an initial normal test were not retested
at a later date therefore we could not be sure of possible
missed false negatives. The current study shows that our
previous assumptions are correct and PC and PS testing
can be done at the time of an acute VTE event with a high
degree of specificity and sensitivity. Assuming a pre-test
probability of 2% the negative likelihood ratio for PC test-
ing is 0 (95% CI, 0%-3%) and for PS testing is 0 (95% CI,
0%-2%).
There is no indication from this series of patients that
acute VTE alters the levels of protein C or S enough to
affect the diagnosis of coagulation factor deficiency.
Whereas genetic tests such as Factor V Leiden and the
G20210A prothrombin gene variant can be tested at any
time, coagulometric assays (such as protein C and S) can-
not be performed in patients anticoagulated with vitamin
K antagonists. Therefore, patients with normal protein C
or S levels at the time of diagnosis can be effectively ruled
out as having deficiency of these proteins and can there-
fore avoid the expense and inconvenience of repeat test-
ing during VKA therapy interruption.
In conclusion, our current study in combination with
our previous results show that testing protein C and S
levels during the acute diagnosis of VTE is a valid
approach. We suggest that thrombophilia testing be per-
Table 1: Results of protein C and protein S testing performed at diagnosis and on repeat testing after discontinuing 
anticoagulation therapy in patients with venous thromboembolism.









Initial normal result 99 242 99 242
Initial abnormal result 0 12 0 12
Repeat abnormal 
result
04 a 06 a
Proportion Abnormal 
on Repeat (95% CI)
0% (0-3.7%)b 40% (35.4-84.8%)b 0% (0-3.7%)b 63.9% (16.8-68.7%)b
CI confidence interval
a Repeat testing was done only if initial test abnormal
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formed at the time of diagnosis of VTE, before VKA ther-
apy is initiated. This is the most convenient time for
testing and allows early identification of patients who
may require more prolonged therapy or further screening
of family members. Only those who have an initially
abnormal test should have confirmatory testing repeated
after a course of VKA therapy and may require LMWH
bridging. In this study we did not assess whether other
coagulation based assays, such as antithrombin, can be
accurately tested at the time of acute VTE diagnosis. This
would be an interesting avenue for future research. In any
case, since warfarin does not affect antithrombin levels,
testing for antithrombin deficiency is possible at a later
date without the need for interrupting anticoagulation.
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